Streetbeat News

Products Services

GRI

GRI Bio has presented preclinical data showing that its drug GRI-0621 can inhibit invariant natural killer T cell activity, which may be beneficial in treating Idiopathic Pulmonary Fibrosis (IPF). The company is advancing a Phase 2a biomarker study with interim data expected in Q4 2024 and topline data in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:49 pm

RYAAY

Ryanair shares are trading lower following news that the company may need to revise traffic figures due to expected Boeing delays.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:46 pm

INTC

MU

Intel and Micron Technology are competing in the semiconductor industry. Intel faces challenges with geopolitical issues and partnerships, while Micron is advancing with memory solutions and global expansion. Micron's stock is performing better, with analysts predicting further upside.

Portfolio Pulse from Surbhi Jain

October 16, 2024 | 12:45 pm

AMZN

Amazon has signed agreements for innovative nuclear energy projects, specifically small modular reactors, to address its growing energy demands and move towards net carbon zero. This initiative is part of Amazon's sustainability efforts.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:43 pm

NVDA

QQQ

SMCI

SPY

Super Micro Computer, Inc (SMCI) is expanding its liquid-cooled AI server offerings, powered by Nvidia's technology, to enhance energy efficiency and computational power. Despite regulatory challenges, SMCI's stock has seen significant growth over the past year. Investors can gain exposure through ETFs like QQQ and SPY.

Portfolio Pulse from Anusuya Lahiri

October 16, 2024 | 12:38 pm

JAGX

Jaguar Health has launched Gelclair, an FDA-approved prescription product in the U.S. for treating oral mucositis, a painful mouth inflammation often associated with chemotherapy. This marks a significant step for the company in addressing chemo-related side effects.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:38 pm

WVE

Wave Life Sciences has achieved a significant milestone in therapeutic RNA editing with its RestorAATion-2 trial of WVE-006 for Alpha-1 Antitrypsin Deficiency. A single dose raised wild-type M-AAT levels to 60% of total AAT, with effects lasting up to 57 days. Multidose data is expected in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:37 pm

WISA

WiSA Technologies anticipates a significant revenue increase in Q3 2024, projecting $1M-$1.2M compared to $300K in the previous quarter. This growth is attributed to the production of WiSA HT and WiSA E IP with a major licensee, leading to increased royalty payments and sales of WiSA E-enabled modules.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:29 pm

ATEN

A10 Networks has introduced a new AI-ready platform, AI-powered bot protection, and expanded DDoS protection to enhance cybersecurity and simplify IT infrastructure.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:27 pm

PHIO

Phio Pharmaceuticals is set to present data on its INSTAYL compound PH-894 at the ASGCT's 2024 Cancer Conference. The compound shows potent silencing of BRD4 in NK cells, enhancing their proliferation and cytotoxicity.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 12:25 pm